Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 3/20 | 0.63 |
| ▸ | CCR4 | P51679 | 2/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.48 |
| ▸ | S100A9 | P06702 | 1/20 | 0.47 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL789565 | 0.88 | PIK3CA (0.57) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL16551868 | 0.88 | PIK3CA (0.55) | PIK3CGPIK3CAMTORSLC40A1 | |
| SCHEMBL28549695 | 0.88 | PIK3CG (0.50) | PIK3CGCCR4PIK3CAPIK3CDPIK3CB | |
| SCHEMBL15556197 | 0.87 | MTOR (0.55) | PIK3CGPIK3CAPIK3CDPIK3CBPIK3R1 | |
| SCHEMBL22447546 | 0.87 | CCR4 (0.59) | PIK3CGCCR4PIK3CAPIK3CDPIK3R1 | |
| SCHEMBL740383 | 0.87 | LMNA (0.53) | PIK3CGCCR4PIK3CAPIK3CDPIK3CB | |
| SCHEMBL15648432 | 0.87 | PIK3CG (0.49) | PIK3CGCCR4PIK3CAPIK3CDPIK3CB | |
| Ammonia Solution, Strong SCHEMBL28564473 | 0.87 | PIK3CG (0.49) | PIK3CGCCR4PIK3CAPIK3CDPIK3CB | |
| SCHEMBL21513796 | 0.86 | CCR4 (0.64) | PIK3CGCCR4PIK3CDSLC40A1PTGES2 | |
| SCHEMBL29969873 | 0.86 | CCR4 (0.64) | PIK3CGCCR4PIK3CDSLC40A1PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080012-A | Thienopyrimidine derivative, preparation method, application and pharmaceutical composition thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4406948-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-117957219-A | Pyridine derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-112469720-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2009055418-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| WO-2008157191-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| WO-2008144463-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144464-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | KRAS, NRAS, BRAF | PIK3CG 4/4885CCR4 3992/4885PIK3CA 8/4885 |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | PIK3CG 2/4885CCR4 3819/4885PIK3CA 6/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | PIK3CG 1125/4885CCR4 4246/4885PIK3CA 480/4885 |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | PIK3CG 21/4885CCR4 3173/4885PIK3CA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.